TuHURA CEO to Present at Canaccord Growth Conference Amid Key Clinical Trials
Event summary
- TuHURA Biosciences CEO James A. Bianco to present at Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026.
- Company is in Phase 3 trial for IFx-2.0 as adjunctive therapy to Keytruda for advanced Merkel Cell Carcinoma.
- TBS-2025 VISTA inhibitor moving into Phase 1b trial for mutNPM1 r/r AML, targeting 35% of AML patients.
- TuHURA developing first-in-class bi-specific ADCs leveraging Delta Opioid Receptor technology.
The big picture
TuHURA's presentation comes as it advances multiple clinical trials aimed at overcoming resistance to cancer immunotherapy, a critical unmet need. The company's focus on novel mechanisms like innate immune agonists and VISTA inhibitors positions it in the competitive immuno-oncology landscape, where differentiation through clinical trial success will be key.
What we're watching
- Clinical Trial Progress
- How the Phase 3 trial results for IFx-2.0 will impact TuHURA's market positioning.
- Regulatory Pathway
- Whether TBS-2025 can navigate FDA approvals efficiently given prior IND challenges.
- Technology Differentiation
- The pace at which TuHURA's Delta Opioid Receptor technology advances in the competitive immuno-oncology space.
Related topics